全文获取类型
收费全文 | 5243篇 |
免费 | 347篇 |
国内免费 | 147篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 203篇 |
妇产科学 | 80篇 |
基础医学 | 621篇 |
口腔科学 | 64篇 |
临床医学 | 376篇 |
内科学 | 690篇 |
皮肤病学 | 48篇 |
神经病学 | 167篇 |
特种医学 | 70篇 |
外科学 | 1342篇 |
综合类 | 611篇 |
预防医学 | 354篇 |
眼科学 | 52篇 |
药学 | 494篇 |
1篇 | |
中国医学 | 241篇 |
肿瘤学 | 299篇 |
出版年
2023年 | 65篇 |
2022年 | 86篇 |
2021年 | 236篇 |
2020年 | 168篇 |
2019年 | 228篇 |
2018年 | 220篇 |
2017年 | 159篇 |
2016年 | 184篇 |
2015年 | 214篇 |
2014年 | 331篇 |
2013年 | 421篇 |
2012年 | 228篇 |
2011年 | 305篇 |
2010年 | 300篇 |
2009年 | 245篇 |
2008年 | 249篇 |
2007年 | 279篇 |
2006年 | 228篇 |
2005年 | 175篇 |
2004年 | 162篇 |
2003年 | 157篇 |
2002年 | 118篇 |
2001年 | 90篇 |
2000年 | 68篇 |
1999年 | 52篇 |
1998年 | 71篇 |
1997年 | 58篇 |
1996年 | 55篇 |
1995年 | 49篇 |
1994年 | 40篇 |
1993年 | 40篇 |
1992年 | 40篇 |
1991年 | 36篇 |
1990年 | 31篇 |
1989年 | 28篇 |
1988年 | 22篇 |
1987年 | 13篇 |
1986年 | 13篇 |
1985年 | 38篇 |
1984年 | 35篇 |
1983年 | 30篇 |
1982年 | 21篇 |
1981年 | 25篇 |
1980年 | 15篇 |
1979年 | 19篇 |
1978年 | 22篇 |
1977年 | 14篇 |
1975年 | 17篇 |
1974年 | 10篇 |
1973年 | 10篇 |
排序方式: 共有5737条查询结果,搜索用时 31 毫秒
11.
目的探讨人核糖体小亚基蛋白(RPS)24剪接变异体mRNA在胃癌中的表达及其意义。方法 采用逆转录-聚合酶链反应(RT-PCR)结合剪接位点特异性引物技术,检测60例胃癌和7例胃溃疡标本中RPS24剪接变异体mRNA表达情况,并分析其与临床病理因素的关系。结果 所有的胃癌和胃溃疡标本中均出现RPS24a mRNA表达;而RPS24c mRNA在胃癌组织表达率为96.7%,癌旁正常黏膜为11.7%;并且低、未分化型胃癌、淋巴结转移≥5个、TNMⅢ、Ⅳ期病例的RPS24c mRNA表达比率分别显著高于分化型胃癌、淋巴结转移<5个、TNM Ⅰ、Ⅱ期胃癌病例(P<0.05)。胃癌组织中RPS24 mRNA的总体表达水平显著高于癌旁正常黏膜(P<0.01),而且TNMⅢ、Ⅳ期胃癌中RPS24 mRNA表达水平显著高于Ⅰ、Ⅱ期胃癌(P<0.05);胃溃疡中RPS24mRNA的表达水平与正常胃黏膜差异无显著性(P>0.05)。结论RPS24剪接变异体的异常表达与胃癌的发展、转移有关,可作为胃癌生物学行为评估和判断预后的指标。 相似文献
12.
人膀胱癌T24细胞及其SCID小鼠移植瘤组织中KDR的表达 总被引:1,自引:1,他引:0
目的 检测KDR在人膀胱癌T24细胞及其SCID小鼠移植瘤组织中的表达。方法 常规培养T24细胞,建立荷人膀胱癌移植瘤SCID小鼠动物模型,使用抗KDR单克隆抗体,通过免疫荧光、免疫组化检测KDR在T24细胞及瘤体组织上的表达;结果 KDR在T24细胞及瘤体组织中均呈阳性表达。结论 本研究结果为进一步研究抗KDR单抗在荷T24细胞移植瘤动物体内分布及对瘤体生长的抑制效应奠定了实验基础。 相似文献
13.
Yukari Takao Akira Yamada Shigeru Yutani Hiroko Takedatsu Takeharu Ono Kojyu Etoh Yi Wang Susumu Suzuki Tatsuya Ide Kunitada Shimotohno Michio Sata Kyogo Itoh 《Hepatology research》2007,37(3):186-195
Aim: Hepatitis C virus (HCV) 1b is resistant to standard interferon therapy and has a high risk of developing into hepatocellular carcinoma at the late stage of infection. Therefore, new therapeutic modalities for HCV1b infection must be developed. One approach would be active specific immunotherapy with highly immunogenic HCV1b peptides. Methods: HCV1b-derived 44 synthetic peptides were selected based on their binding scores to HLA-A24. Peptide-specific IgG were measured by ELISA. Peptide-specific cytotoxic T-lymphocytes (CTLs) were induced in vitro by repeated peptide-stimulation. Results: We identified three novel candidate peptides of HCV1b proteins containing HLA-A24 binding motifs. Each of them had the ability to induce HLA-A24-restricted and peptide-specific CTL activity, and IgGs specific to each of them were detected in the plasma of HCV1b patients. Among these three peptides, a peptide NS5A 2132-2142 was recognized by both cellular and humoral immunities in the majority of blood samples of patients tested. More importantly, the peptide-stimulated peripheral blood mononuclear cells (PBMCs) showed cytotoxicity against cells cotransfected with NS5A and HLA-A2402 genes in an HLA-restricted manner. This is an additional report to our previous study. Conclusion: These findings may provide a new insight into the development of a peptide-based specific immunotherapy for HCV1b-infected patients. 相似文献
14.
M. Myslak H. Amer P. Morales M. E. Fidler J. M. Gloor T. S. Larson M. D. Stegall F. G. Cosio 《American journal of transplantation》2006,6(7):1660-1665
Increasing numbers of patients receive kidney transplants before initiation of dialysis or shortly thereafter. Some of these patients have significant proteinuria pre-transplant making the interpretation of post-transplant proteinuria problematic. In this study, we evaluated post-transplant proteinuria in 115 patients who had urine protein measured within 3 months of transplant and assessed the association of proteinuria with allograft pathology. Proteinuria declined rapidly from 3650 +/- 3702 mg/day pre-transplant to 550 + 918 at 3 weeks (p < 0.0001) and continued to decline until 1 year post-transplant (472 +/- 1116, p < 0.0001 vs. 3 weeks). Proteinuria greater than 3000 mg/day was present in 48 patients (42%) pre-transplant, in 1 patient (1%) at 3 weeks and in 4 patients (4%) at 1 year. Surveillance graft biopsies were done at 1 year in 93% of patients. Proteinuria > or = 1500 mg/day and/or an absolute increase in proteinuria > 500 mg/day after 3 weeks post-transplant was associated with allograft glomerular pathology. In conclusion, pre-transplant proteinuria, even when high grade, declines rapidly after transplantation. Failure to decline or persistence of proteinuria greater than 1500 mg/day is indicative of allograft pathology. 相似文献
15.
16.
17.
Momoko Ogawa Nobuhito Hirawa Takamasa Tsuchida Naomi Eguchi Yukari Kawabata Atsushi Numabe Hideyuki Negoro Rie Hakamada-Taguchi Kousuke Seiki Satoshi Umemura Yoshihiro Urade Yoshio Uehara 《Nephrology, dialysis, transplantation》2006,21(4):924-934
BACKGROUND: Otsuka Long-Evans Tokushima Fatty (OLETF) rats genetically develop diabetes which is associated with hypertension. In preliminary studies, urinary excretions of L-PGDS (lipocaline-type prostaglandin D synthase) increase before diabetic nephropathy obviously develops, and this may predict progression of renal injury following diabetes. In the present study, we attempted to define whether urinary excretions of L-PGDS behave as the predictor of development of diabetic nephropathy in OLETF rats. METHODS: We investigated alterations of urinary L-PGDS excretions during the establishment of diabetes and assessed the relationship between the L-PGDS excretions and renal function in OLETF rats. Furthermore, we treated OLETF rats with troglitazone and analysed the effects on L-PGDS metabolisms. Urinary L-PGDS was measured by immunoenzyme assay and the occurrence of L-PGDS and its mRNA in the kidney was assessed by immunohistochemistry and a PCR method. RESULTS: Urinary excretions of L-PGDS were significantly higher in OLETF rats than non-diabetic Long-Evans Tokushima Otsuka (LETO) rats. The excretions age-dependently increased in OLETF and this increase appeared to be due to increased glomerular permeability to L-PGDS. Messenger RNA and antigenicity of L-PGDS were demonstrated in renal tissue; however, the de novo synthesis of L-PGDS mRNA seemingly contributed to urinary L-PGDS excretions much less than glomerular filtration. Multiple regression analysis revealed that urinary L-PGDS was determined by urinary protein excretions, and not by high blood pressure per se. Conversely, urinary proteinuria in the established diabetic nephropathy was predicted by urinary L-PGDS excretions in the early stage of diabetes. CONCLUSIONS: Urinary excretions of L-PGDS are likely to reflect the underlying increase in glomerular permeability. This property may be useful to predict forthcoming glomerular damage following diabetes in OLETF rats. 相似文献
18.
Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. 总被引:6,自引:2,他引:4
Dimitrios S Goumenos Sotiris Tsakas Abdel Meguid El Nahas Sotiria Alexandri Simon Oldroyd Pantelitsa Kalliakmani John G Vlachojannis 《Nephrology, dialysis, transplantation》2002,17(12):2145-2152
BACKGROUND: Transforming growth factor-beta(1) (TGF-beta(1)) is the major fibrogenic growth factor implicated in the pathogenesis of renal scarring. Proteinuria is a poor prognostic feature for various types of glomerular disease and its toxic action may be related to the activation of tubular epithelial cells towards increased production of cytokines and chemoattractant peptides. In this work we studied the site of synthesis and expression profile of TGF-beta(1) in the renal tissue of patients with heavy proteinuria and examined the relation of this expression with the urinary excretion of TGF-beta(1). METHODS: Twenty-five patients with heavy proteinuria (8.4+/-3.0 g/24 h) were included in the study. All patients underwent a diagnostic kidney biopsy and were commenced on immunosuppressive therapy with corticosteroids and cyclosporin. The sites of synthesis and expression profile of TGF-beta(1) mRNA and protein in the kidney were examined by in situ hybridization and immunohistochemistry. Urinary and plasma TGF-beta(1) levels were determined by ELISA before the initiation of treatment and 6 months later and compared with those of normal subjects and of patients with IgA nephropathy and normal urinary protein excretion. RESULTS: The site of synthesis and expression of TGF-beta(1) in the renal tissue of patients with heavy proteinuria was mainly localized within the cytoplasm of tubular epithelial cells. Interstitial expression was also present but glomerular TGF-beta(1) expression was found only in patients with mesangial proliferation. Urinary TGF-beta(1) excretion was significantly higher in nephrotic patients compared with normal subjects and with patients with IgA nephropathy and normal urinary protein excretion (783+/-280 vs 310+/-140 and 375+/-90 ng/24 h, respectively; P<0.01). In patients with remission of proteinuria after immunosuppressive therapy, urinary TGF-beta(1) excretion was significantly reduced (from 749+/-290 to 495+/-130 ng/24 h; P<0.01), while in patients with persistent nephrotic syndrome, it remained elevated. CONCLUSIONS: The localization of TGF-beta(1) mRNA and protein within tubular epithelial cells, along with its increased urinary excretion in patients with nephrotic syndrome, suggest the activation of these cells by filtered protein towards increased TGF-beta(1) production. 相似文献
19.
Proteinuria and interstitial injury. 总被引:11,自引:3,他引:8
Allison A Eddy 《Nephrology, dialysis, transplantation》2004,19(2):277-281
20.